Tendenze, dimensioni e crescita del mercato dei vaccini suini entro il 2034

Porcine Vaccine market size is expected to reach US$ 2.75 Billion by 2034 from US$ 1.50 Billion in 2025. The market is anticipated to register a CAGR of 6.97% during the forecast period 2026–2034.

The research report on the Porcine Vaccine Market is segmented by vaccine type into live attenuated vaccines, inactivated vaccines, recombinant vaccines, and DNA vaccines. Applications analyzed include swine influenza, porcine reproductive and respiratory syndrome (PRRS), porcine circovirus, foot-and-mouth disease, and other infectious diseases. End-users include veterinary hospitals, swine farms, research institutes, and pharmaceutical manufacturers. The regional analysis covers key markets such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.

Purpose of the Report

The report Porcine Vaccine Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

• Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
• Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
• Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Porcine Vaccine Market Segmentation

Technology

• Inactivated Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Conjugate Vaccines
• DNA Vaccines

Disease Indication

• Diarrhea
• Swine Influenza
• Arthritis
• Bordatella Rhinitis
• Porcine Reproductive and Respiratory Virus
• Porcine Circovirus Associated Disease

End User

• Veterinary Hospitals
• Hog/Pig Production Farm

Mercato dei vaccini suini: Approfondimenti strategici

Porcine Vaccine Market Growth Drivers

• Rising Prevalence of Swine Diseases and Outbreaks: The increasing incidence of infectious diseases among swine populations is a major driver of the porcine vaccine market. Diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Classical Swine Fever (CSF), Porcine Circovirus (PCV), and African Swine Fever (ASF) are causing significant economic losses in the global pig farming industry. According to the Food and Agriculture Organization (FAO), ASF alone has led to the culling of millions of pigs in Asia and Europe, severely impacting pork production and supply chains. The growing threat of zoonotic diseases, which can spread from animals to humans, further emphasizes the need for effective vaccination programs. Governments and livestock associations worldwide are promoting mandatory vaccination campaigns to curb disease outbreaks, creating a strong demand for porcine vaccines. As the pork industry remains a critical component of global food security, the adoption of vaccines is expected to rise steadily.
• Growing Pork Consumption Driving Demand for Healthy Livestock: Pork is one of the most widely consumed meats worldwide, with increasing demand in regions like Asia-Pacific, Europe, and Latin America. According to the US Department of Agriculture (USDA), China alone accounts for over 50% of global pork consumption, followed by the European Union and the United States. To meet this growing demand, commercial pig farms are expanding their operations, necessitating robust disease prevention measures, including vaccination programs. Consumers are becoming more conscious of meat quality and safety, leading to stringent regulations on antibiotic use in livestock. Vaccination serves as a critical preventive strategy to reduce reliance on antibiotics while ensuring healthy swine populations. With the intensification of pig farming and higher biosecurity measures, the demand for porcine vaccines is expected to rise significantly in the coming years.
• Advancements in Vaccine Development and Biotechnology:
  Continuous advancements in biotechnology and veterinary medicine are enhancing the efficacy and safety of porcine vaccines. The development of recombinant and subunit vaccines, which provide targeted immunity with minimal side effects, is gaining traction. Researchers are also exploring mRNA-based vaccines for swine diseases, similar to the technology used in COVID-19 vaccines, to improve immune response and production efficiency. Additionally, combination vaccines that protect against multiple swine diseases in a single shot are becoming popular, reducing stress on animals and improving compliance among pig farmers. These innovations are driving the market by offering more effective, long-lasting protection against viral and bacterial infections, ultimately improving swine health and farm productivity.

Porcine Vaccine Market Future Trends

• Increasing Adoption of Autogenous and Custom-Made Vaccines: There is growing adoption of autogenous and custom-made vaccines as a response to emerging and strain-specific infections, due to the custom-made approach using locally isolated pathogens specific to a farm's needs. Autogenous vaccines are more targeted than commercial vaccines, which may not always match evolving virus strains. The growing requirement for customized veterinary care, especially with the emergence of novel swine disease variants in specific regions, is indeed driving the demand for customized solutions. Autogenous vaccines are being supported by regulatory agencies like the USDA Center for Veterinary Biologics for region-specific outbreaks. Increasing veterinary precision medicine will expand the use of customized porcine vaccines very rapidly.
• The Trend Towards DNA and mRNA-Based Swine Vaccines:
  The basis of mRNA vaccine success in human medicine has encouraged research into their application in animal health. These include the DNA and mRNA vaccines, whose advantages include faster production times, higher immunogenicity, and superior adaptability to mutating viruses. mRNA vaccines are being developed for various swine diseases such as PRRS and ASF. Preliminary results from some early studies appear promising. For instance, in 2022, a team of European scientists designed an mRNA vaccine candidate for ASF that elicited potent immune responses in pigs. With the advancement of the technology, mRNA-based porcine vaccines will change the game by providing rapid protection against emerging swine diseases.
• Increasing Government Policies and Compulsory Vaccination Programs: Governments across the globe are adopting more stringent vaccination policies to safeguard the swine industry from disease outbreaks. Regulators have made vaccination mandatory for certain diseases in the regions such as Europe and Asia where ASF and PRRS have severely struck pig populations. In a further bid to prevent outbreaks, countries like China, Vietnam, and the Philippines have stepped up efforts to accelerate the development of ASF vaccines as well as hasten their distribution. Moreover, the European Food Safety Authority is promoting vaccination in disease control strategies aimed at maintaining stable pig production, making it more likely for increased vaccination adoption with stronger regulatory and financial incentives for swine farmers, so it is going to further fuel the growth of the market.

Porcine Vaccine Market Opportunities

• Development of Universal or Multivalent Vaccines: There is a growing need for universal or multivalent vaccines that offer broad protection against multiple porcine diseases with a single administration. Currently, farmers must administer multiple vaccines to protect pigs against various infections, increasing labor costs and stress on the animals. The development of next-generation vaccines that can simultaneously prevent major swine diseases, such as PRRS, PCV, and ASF, would greatly enhance disease management efficiency and improve herd immunity. Research into recombinant DNA technology, mRNA vaccines, and cross-protective immunization strategies is paving the way for more effective and versatile vaccine solutions. Companies that successfully develop and commercialize such vaccines could gain a significant competitive advantage in the market.
• Growth of Autogenous Vaccines for Farm-Specific Disease Control: Autogenous vaccines, which are tailor-made for specific farms based on the pathogens affecting a particular herd, are becoming an attractive alternative to conventional vaccines. These vaccines are especially useful for combating antibiotic-resistant bacterial infections and localized viral strains. With increasing restrictions on antibiotic use in livestock production, customized vaccines provide a targeted and sustainable approach to disease prevention. Veterinary pharmaceutical companies can expand their market presence by offering rapid diagnostic services and developing farm-specific vaccine formulations. Collaborating with veterinary clinics and livestock health specialists to integrate autogenous vaccines into herd management programs can further drive adoption.
• Adoption of Digital Health Solutions for Vaccine Monitoring:
  The integration of digital health technologies in livestock management is opening new opportunities for vaccine manufacturers and veterinary service providers. Smart vaccine monitoring systems, including RFID tracking, mobile applications, and cloud-based data analytics, allow farmers to track vaccine administration, monitor herd immunity levels, and ensure compliance with disease control protocols. Digital solutions can help optimize vaccination schedules, reduce wastage, and improve overall herd health outcomes. Companies investing in smart vaccination platforms and precision livestock farming technologies can differentiate themselves in the market by offering data-driven disease management solutions. Partnerships with agritech firms and veterinary software providers can further accelerate the adoption of these innovations in commercial pig farms.

Porcine Vaccine Market Players Density: Understanding Its Impact on Business Dynamics

The Porcine Vaccine Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Key Selling Points

• Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Porcine Vaccine Market, providing a holistic landscape.
• Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
• Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
• Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Porcine Vaccine Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.

Responsabile della ricerca

Mrinal Kelhalkar

Manager,
Ricerca e consulenza

Mrinal è un'analista di ricerca esperta con oltre 8 anni di esperienza nella consulenza e nell'intelligence di mercato nel settore delle scienze biologiche. Grazie a una mentalità strategica e a un costante impegno verso l'eccellenza, ha maturato una profonda competenza nelle previsioni farmaceutiche, nella valutazione delle opportunità di mercato e nello sviluppo di benchmark di settore. Il suo lavoro è incentrato sulla fornitura di insight fruibili che consentono ai clienti di prendere decisioni strategiche consapevoli.

Il punto di forza di Mrinal risiede nella capacità di tradurre complessi set di dati quantitativi in ​​business intelligence significative. Il suo acume analitico è fondamentale per definire strategie di go-to-market (GTM) e individuare opportunità di crescita nei settori farmaceutico e dei dispositivi medici. In qualità di consulente di fiducia, si concentra costantemente sulla semplificazione dei processi di flusso di lavoro e sulla definizione di best practice, promuovendo così l'innovazione e l'efficienza operativa per i suoi clienti.

Testimonianze

Il report di mercato sui sistemi SCADA di Insight Partners è completo, con preziosi spunti sulle tendenze attuali e sulle previsioni future. Il team si è dimostrato altamente professionale, reattivo e disponibile in ogni fase del progetto. Siamo molto soddisfatti e consigliamo vivamente i loro servizi.

RAN KEDEM Partner, Reali Technologies LTDs

Ho richiesto un report su un mercato software molto specifico e il team lo ha prodotto in pochi giorni. Le informazioni erano molto pertinenti e ben presentate. Ho quindi richiesto alcune modifiche e aggiunte al report. Il team è stato ancora una volta molto reattivo e ho ricevuto il report finale in meno di una settimana.

JEAN-HERVE JENN Presidente, Future Analytica

Abbiamo collaborato con The Insight Partners per un importante studio di mercato e una previsione. Ci hanno fornito informazioni chiare su opportunità e rischi, che ci hanno aiutato a definire i nostri piani. La loro ricerca è stata facile da usare e basata su dati solidi. Ci ha aiutato a prendere decisioni intelligenti e consapevoli. Li consigliamo vivamente.

PIYUSH NAGPAL Vicepresidente senior, Abbaglianti globali

Insight Partners ha fornito ricerche di mercato approfondite e ben strutturate, con una solida competenza nel settore. Il loro team si è dimostrato professionale e reattivo in ogni fase. Il sito web intuitivo ha reso l'accesso ai report di settore semplice e immediato. Li consigliamo vivamente per servizi di ricerca affidabili e di alta qualità.

YUKIHIKO ADACHI Amministratore delegato, Deep Blue, LLC.

Questa è la prima volta che acquisto un report di mercato da The Insight Partners. Sebbene inizialmente fossi indeciso, ho visitato il loro sito web e mi sono sentito più a mio agio nell'acquistare un report di mercato. Sono completamente soddisfatto della qualità del report e del servizio clienti. Avevo diverse domande e commenti sul report iniziale, ma dopo un paio di conversazioni via email con il loro analista credo di avere un report che posso utilizzare come input per il nostro processo di pianificazione strategica. Grazie mille per aver dedicato del tempo extra e aver reso questa esperienza positiva. Consiglierò sicuramente il vostro servizio ad altri e sarete la mia prima persona a cui rivolgermi quando avremo bisogno di ulteriori dati di mercato.

GIOVANNI SUZUKI Presidente e Amministratore Delegato, Consigliere di Amministrazione, Tecnologie BK

Desidero esprimere la mia gratitudine per il supporto e la professionalità dimostrati nel rispondere alla mia richiesta di informazioni sul mercato dei dispositivi medici in vitro per malattie infettive in Nigeria. Apprezzo la vostra pazienza, la vostra guida e la vostra disponibilità a offrirmi uno sconto, che alla fine ci ha permesso di concludere l'affare. Non vedo l'ora di collaborare con The Insight Partners in futuro, grazie anche all'impressione che mi avete lasciato dopo questo primo incontro.

Dott. Chijioke AMMINISTRATORE DELEGATO DI ONYIA, PineCrest Healthcare Ltd.

Previous Next